CORONA Remedies Reports 17.3% Revenue Growth in FY26, Recommends Final Dividend
CORONA Remedies Limited, a leading India-focused branded pharmaceutical company, announced its audited financial results for the fourth quarter and fiscal year ended March 31, 2026, showcasing robust financial performance. The Board of Directors also recommended a final dividend for the shareholders.At a board meeting held on May 11, 2026, the company approved the audited Standalone and Consolidated Financial Results, alongside the respective Audit Reports, for the year ended March 31, 2026.
Financial Performance Highlights
The Company’s financial statements for the year ended March 31, 2026, indicate significant growth. The attached financial statements provide a detailed comparison of results.For the year ended March 31, 2026, CORONA Remedies reported a Revenue from Operations of 1,403.2 Crores, marking a 17.3% growth year-on-year (YoY). The Profit After Tax (PAT) for FY26 was 199.4 Crores, representing a 33.4% growth compared to FY25. The quarterly revenue for Q4FY26 stood at 353.1 Crores, a 20.2% YoY increase.
Financial Performance Snapshot (Crores)
| Particulars | Q4FY26 | FY26 | Q4FY25 | FY25 |
|---|---|---|---|---|
| Revenue from Operations | 353.1 | 1,403.2 | 293.7 | 1,196.4 |
| Profit After Tax (PAT) | 45.3 | 199.4 | 315 | 149.4 |
| EBITDA Margin | 17.6% | 20.9% | 18.5% | 20.1% |
Dividend and Shareholder Actions
The Board of Directors recommended a final dividend of X 10/- (100%) per equity share of face value of X 10/- each to the shareholders for approval at the ensuing Annual General Meeting.The Company fixed Friday, June 19, 2026, as the Record Date for determining entitlement to the final dividend for the financial year 2025-26. If the dividend is approved by shareholders, it is slated for payment on or before August 07, 2026.
Key Strategic and Operational Updates
During the reporting period, CORONA Remedies bolstered its market presence and operational capacity:- Strategic Acquisition: The company acquired WOKADINE, marking its entry into the Povidone Iodine market. This acquisition was funded through internal accruals.
- Portfolio Expansion: The company relaunched key brands, Fostine R and Menodac, under Women's Health Therapeutics, and launched Noklot in the Cardiovascular segment, thereby expanding its addressable market.
- Brand Strength: The company achieved a milestone of having two brands cross the 100 Crore MAT revenue mark in March 2026.
Appointment of Statutory and Internal Auditors
The Board approved recommendations for appointments of various audit professionals for the financial year 2026-27:| Role | Firm/Individual | Period |
|---|---|---|
| Statutory Auditor | M/s. Walker Chandiok & Co LLP | Five consecutive years (F.Y. 2026-27 to F.Y. 2030-31) |
| Secretarial Auditor | M/s. Dhara Patel | Five consecutive years (Commencing F.Y. 2026-27) |
| Internal Auditor | M/s. Shah & Shah Associates | Financial Year 2026-27 |
| Cost Auditor | M/s. Manish B. Analkat | Financial Year 2026-27 |
Additionally, the Board approved the re-appointment of Dr. Kirtikumar Mehta as Non-Executive Director and Chairman of the Company for five consecutive financial years, effective from April 01, 2027.
Financial Statement Tables
Standalone Financial Results: Statement of Standalone Assets and Liabilities as at March 31, 2026 (Rs. in Crores)| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| TOTAL ASSETS | 1,204.25 | 929.24 |
| Non-current assets | 855.94 | 590.37 |
| Total current assets | 348.31 | 338.87 |
| TOTAL EQUITY AND LIABILITIES | 1,204.25 | 929.24 |
| Total equity | 745.97 | 605.72 |
| Total non-current liabilities | 97.11 | 83.93 |
| Total current liabilities | 361.17 | 239.59 |
Consolidated Financial Results: Statement of Consolidated Assets and Liabilities as at March 31, 2026 (Rs. in Crores)
| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| TOTAL ASSETS | 1,205.14 | 929.86 |
| Non-current assets | 856.83 | 590.99 |
| Total current assets | 348.31 | 338.87 |
| TOTAL EQUITY AND LIABILITIES | 1,205.14 | 929.86 |
| Total equity | 746.86 | 606.34 |
| Total non-current liabilities | 97.11 | 83.93 |
| Total current liabilities | 458.28 | 323.52 |
CORONA Stock Price Movement
Today, CORONA Remedies Limited shares edged higher, settling at ₹1755.8 after gaining 3.08% in its post-market trading. The strong session saw the stock reach its 52-week high of ₹1807.4, trading on a substantial volume of 47,515 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.